Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort.
Anthropometry
Biomarkers
Breast cancer
Inflammation
Menopausal status
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
18 04 2022
18 04 2022
Historique:
received:
03
09
2021
accepted:
28
02
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
20
4
2022
Statut:
epublish
Résumé
Inflammation has been hypothesized to play a role in the development and progression of breast cancer and might differently impact breast cancer risk among pre and postmenopausal women. We performed a nested case-control study to examine whether pre-diagnostic circulating concentrations of adiponectin, leptin, c-reactive protein (CRP), tumour necrosis factor-α, interferon-γ and 6 interleukins were associated with breast cancer risk, overall and by menopausal status. Pre-diagnostic levels of inflammatory biomarkers were measured in plasma from 1558 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We used conditional logistic regression to estimate the odds ratios (ORs) of breast cancer at blood collection, per one standard deviation increase in biomarker concentration. Cases were diagnosed at a mean age of 61.4 years on average 8.6 years after blood collection. No statistically significant association was observed between inflammatory markers and breast cancer risk overall. In premenopausal women, borderline significant inverse associations were observed for leptin, leptin-to-adiponectin ratio and CRP [OR= 0.89 (0.77-1.03), OR= 0.88 (0.76-1.01) and OR= 0.87 (0.75-1.01), respectively] while positive associations were observed among postmenopausal women [OR= 1.16 (1.05-1.29), OR= 1.11 (1.01-1.23), OR= 1.10 (0.99-1.22), respectively]. Adjustment for BMI strengthened the estimates in premenopausal women [leptin: OR = 0.83 (0.68-1.00), leptin-to-adiponectin ratio: OR = 0.80 (0.66-0.97), CRP: OR = 0.85 (0.72-1.00)] but attenuated the estimates in postmenopausal women [leptin: OR = 1.09 (0.96-1.24), leptin-to-adiponectin ratio: OR = 1.02 (0.89-1.16), CRP: OR = 1.04 (0.92-1.16)]. Associations between CRP, leptin and leptin-to-adiponectin ratio with breast cancer risk may represent the dual effect of obesity by menopausal status although this deserves further investigation.
Sections du résumé
BACKGROUND
Inflammation has been hypothesized to play a role in the development and progression of breast cancer and might differently impact breast cancer risk among pre and postmenopausal women. We performed a nested case-control study to examine whether pre-diagnostic circulating concentrations of adiponectin, leptin, c-reactive protein (CRP), tumour necrosis factor-α, interferon-γ and 6 interleukins were associated with breast cancer risk, overall and by menopausal status.
METHODS
Pre-diagnostic levels of inflammatory biomarkers were measured in plasma from 1558 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We used conditional logistic regression to estimate the odds ratios (ORs) of breast cancer at blood collection, per one standard deviation increase in biomarker concentration.
RESULTS
Cases were diagnosed at a mean age of 61.4 years on average 8.6 years after blood collection. No statistically significant association was observed between inflammatory markers and breast cancer risk overall. In premenopausal women, borderline significant inverse associations were observed for leptin, leptin-to-adiponectin ratio and CRP [OR= 0.89 (0.77-1.03), OR= 0.88 (0.76-1.01) and OR= 0.87 (0.75-1.01), respectively] while positive associations were observed among postmenopausal women [OR= 1.16 (1.05-1.29), OR= 1.11 (1.01-1.23), OR= 1.10 (0.99-1.22), respectively]. Adjustment for BMI strengthened the estimates in premenopausal women [leptin: OR = 0.83 (0.68-1.00), leptin-to-adiponectin ratio: OR = 0.80 (0.66-0.97), CRP: OR = 0.85 (0.72-1.00)] but attenuated the estimates in postmenopausal women [leptin: OR = 1.09 (0.96-1.24), leptin-to-adiponectin ratio: OR = 1.02 (0.89-1.16), CRP: OR = 1.04 (0.92-1.16)].
CONCLUSIONS
Associations between CRP, leptin and leptin-to-adiponectin ratio with breast cancer risk may represent the dual effect of obesity by menopausal status although this deserves further investigation.
Identifiants
pubmed: 35430795
doi: 10.1186/s12916-022-02319-y
pii: 10.1186/s12916-022-02319-y
pmc: PMC9014562
doi:
Substances chimiques
Adipokines
0
Adiponectin
0
Biomarkers
0
Leptin
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
118Informations de copyright
© 2022. The Author(s).
Références
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1100-1106
pubmed: 28292922
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):220-4
pubmed: 14973094
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Annu Rev Immunol. 2012;30:677-706
pubmed: 22224761
Sci Rep. 2017 Oct 5;7(1):12708
pubmed: 28983080
Lancet. 1996 Jun 22;347(9017):1713-27
pubmed: 8656904
Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391
pubmed: 33356944
Breast Cancer Res Treat. 2016 Jan;155(2):345-54
pubmed: 26740213
Diabetologia. 2009 Nov;52(11):2345-2349
pubmed: 19756488
Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8
pubmed: 16214925
Breast Cancer Res. 2007;9(4):212
pubmed: 17705880
Am J Epidemiol. 2013 Jan 1;177(1):3-13
pubmed: 23171880
Breast Cancer Res Treat. 2006 Jul;98(2):157-65
pubmed: 16502016
PLoS One. 2016 Jul 08;11(7):e0158959
pubmed: 27391324
Semin Reprod Med. 2002 May;20(2):103-12
pubmed: 12087495
J Clin Oncol. 2009 May 1;27(13):2217-24
pubmed: 19289618
Cancer Causes Control. 2014 Apr;25(4):533-9
pubmed: 24504436
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1439-49
pubmed: 26224798
Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1199-206
pubmed: 25994740
Cancer Epidemiol. 2010 Oct;34(5):580-6
pubmed: 20579950
Public Health Nutr. 2002 Aug;5(4):561-5
pubmed: 12186665
Biol Res Nurs. 2005 Oct;7(2):118-29
pubmed: 16267373
Cancer Prev Res (Phila). 2013 Mar;6(3):188-95
pubmed: 23466816
J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6
pubmed: 17213279
Nat Rev Cancer. 2015 Aug;15(8):484-98
pubmed: 26205341
IARC Monogr Eval Carcinog Risks Hum. 2007;91:1-528
pubmed: 18756632
Cancer Causes Control. 2009 Feb;20(1):15-26
pubmed: 18704713
Mol Cell Endocrinol. 2014 Jan 25;382(1):673-682
pubmed: 23791814
J Natl Cancer Inst. 2008 Mar 19;100(6):443-4; author reply 444-5
pubmed: 18334713
Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1319-24
pubmed: 23651666
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Breast Cancer Res Treat. 2009 Feb;113(3):567-76
pubmed: 18330696
J Natl Cancer Inst. 2007 Jun 6;99(11):890-4
pubmed: 17551149
Public Health Nutr. 2003 Jun;6(4):407-13
pubmed: 12795830
J Natl Cancer Inst. 2015 Jul 16;107(9):
pubmed: 26185195
Am J Epidemiol. 2018 Apr 1;187(4):705-716
pubmed: 28641369
Cancer Prev Res (Phila). 2011 Sep;4(9):1449-56
pubmed: 21680707
BMC Res Notes. 2010 Nov 13;3:302
pubmed: 21073739
J Clin Oncol. 2012 Jan 10;30(2):151-7
pubmed: 22162577